Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion

Pigment Cell and Melanoma Research

Volumn 28, Issue 5, 2015, Pages 607-610

  Menzies, Alexander M ^a,b   Yeh, Iwei ^c   Botton, Thomas ^c   Bastian, Boris C ^c   Scolyer, Richard A ^a,b,d   Long, Georgina V ^a,b  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FLUORODEOXYGLUCOSE F 18; FOTEMUSTINE; IPILIMUMAB; PACLITAXEL; PEMBROLIZUMAB; STEM CELL FACTOR; TRAMETINIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; BRAF-KIAA1549 FUSION PROTEIN, HUMAN; CARRIER PROTEIN; LIPRIN-BETA2 PROTEIN, HUMAN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MONOCLONAL ANTIBODY; ONCOPROTEIN; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; AGED; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CASE REPORT; COLON METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCORTICOGRAPHY; GASTROINTESTINAL HEMORRHAGE; GENE FUSION; GENE SEQUENCE; HAND PARESTHESIA; HUMAN; HUMAN TISSUE; INTRON; LETTER; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MESENTERY LYMPH NODE; METASTATIC MELANOMA; MICROCYTIC ANEMIA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NEUROLOGIC GAIT DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE N RAS; PARAAORTIC LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; SENTINEL LYMPH NODE BIOPSY; SKIN ULCER; STEREOTACTIC RADIOSURGERY; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; DISEASE COURSE; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; MELANOMA; METABOLISM; METASTASIS; PATHOLOGY; SECONDARY; SKIN NEOPLASMS; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARRIER PROTEINS; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MAP KINASE KINASE KINASES; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84939267814     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12388     Document Type: Letter

References (12)

1. Banerjee, A., Jakacki, R., Onar-Thomas, A. et al. (2014). A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: a Pediatric Brain Tumor Consortium report. J. Clin. Oncol. 32(Suppl 5), abstr 10065.
2. Botton, T., Yeh, I., Nelson, T. et al. (2013). Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res. 26, 845-851.
3. Frederick, D.T., Piris, A., Cogdill, A.P. et al. (2013). BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225-1231.
4. Hutchinson, K.E., Lipson, D., Stephens, P.J. et al. (2013). BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin. Cancer Res. 19, 6696-6702.
5. Jones, D.T., Kocialkowski, S., Liu, L., Pearson, D.M., Backlund, L.M., Ichimura, K., and Collins, V.P. (2008). Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 68, 8673-8677.
6. Joseph, R.W., Elassaiss-Schaap, J., Wolchok, J.D. et al. (2014). Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. J. Clin. Oncol. 32(Suppl 15), abstract 3015.
7. Nissan, M.H., Pratilas, C.A., Jones, A.M. et al. (2014). Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 74, 2340-2350.
8. Passeron, T., Lacour, J.P., Allegra, M. et al. (2011). Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy? Exp. Dermatol. 20, 1030-1032.
9. Sievert, A.J., Lang, S.-S., Boucher, K.L., Madsen, P.J., Slaunwhite, E., Choudhari, N., Kellet, M., Storm, P.B., and Resnick, A.C. (2013). Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc. Natl Acad. Sci. USA 110, 5957-5962.
10. Subbiah, V., Westin, S.N., Wang, K., Araujo, D., Wang, W.L., Miller, V.A., Ross, J.S., Stephens, P.J., Palmer, G.A., and Ali, S.M. (2014). Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. J. Hematol. Oncol. 7, 8.
11. Wilmott, J.S., Long, G.V., Howle, J.R., Haydu, L.E., Sharma, R.N., Thompson, J.F., Kefford, R.F., Hersey, P., and Scolyer, R.A. (2012). Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18, 1386-1394.
12. Xia, J., Jia, P., Hutchinson, K.E., Dahlman, K.B., Johnson, D., Sosman, J., Pao, W., and Zhao, Z. (2014). A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol. Cancer Ther. 13, 1918-1928.